BiotechTube
EuroscreenFast

EuroscreenFast

Brussels, Belgium· Est.
euroscreenfast.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

EuroscreenFast is a specialized, service-based CRO with a deep focus on GPCR biology, offering one of the industry's largest catalogs of validated GPCR screening assays and a proprietary deorphanization platform. The company serves pharmaceutical and biotech clients globally, providing critical tools and expertise for early-stage drug discovery, particularly in CNS, metabolic, and inflammatory diseases. Its business model is built on recurring service contracts and custom assay development, positioning it as a key enabler in the high-value GPCR drug target space. Recent strategic partnerships, like the one with BioPharma Consultants in India, indicate an active effort to expand its global reach and service capabilities.

CNSMetabolic DiseasesInflammation

Technology Platform

Proprietary library of over 1,000 functional and binding assays for 530+ GPCR targets, utilizing natural coupling-oriented readouts (Aequorin, cAMP, GTPγS, etc.). Includes a unique GPCR deorphanization platform with a track record of 17 successful receptor-ligand pair identifications.

Opportunities

Growing demand for specialized GPCR screening and profiling services due to the target class's high drugability.
Expansion into new geographic markets (e.g., via Indian partnership) and the development of new therapeutic-area profiling panels present clear growth avenues.
The continued deorphanization of GPCRs offers opportunities for high-value target discovery collaborations.

Risk Factors

Revenue is tied to biopharma R&D budgets, which are cyclical and can be cut.
Competition from other CROs and the potential for technological disruption in assay methods pose threats.
The business is reliant on key scientific personnel and its reputation for high-quality data.

Competitive Landscape

EuroscreenFast competes in a niche segment against other specialized GPCR-focused CROs (e.g., DiscoverX, now part of Eurofins; PerkinElmer's GPCR offerings) and the broader service divisions of large CROs. Its competitive advantage lies in its extensive, validated assay catalog, long-standing expertise, and unique deorphanization platform, which may be difficult for larger, less-specialized players to replicate quickly.

More companies in Diagnostics & Precision Medicine →More companies in Belgium →